2026年3月，南京绿叶制药有限公司宣布完成A轮融资，投资方为中国信达资产管理股份有限公司。该公司总部位于江苏南京，专注于抗肿瘤创新药物研发、生产与销售，核心产品包括注射用紫杉醇脂质体（力扑素）、香菇多糖注射液（天地欣）和盐酸吉西他滨脂质体（天地达）。本轮融资将用于加速在研管线临床推进及产业化能力建设。此次融资标志着国有金融资本对国产抗肿瘤药企技术实力与市场潜力的认可。
Source Link2026年3月，南京绿叶制药有限公司宣布完成A轮融资，投资方为中国信达资产管理股份有限公司。该公司总部位于江苏南京，专注于抗肿瘤创新药物研发、生产与销售，核心产品包括注射用紫杉醇脂质体（力扑素）、香菇多糖注射液（天地欣）和盐酸吉西他滨脂质体（天地达）。本轮融资将用于加速在研管线临床推进及产业化能力建设。此次融资标志着国有金融资本对国产抗肿瘤药企技术实力与市场潜力的认可。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.